SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-18-004320
Filing Date
2018-05-08
Accepted
2018-05-08 16:31:08
Documents
63
Period of Report
2018-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q gemp-20180331x10q.htm 10-Q 1055229
2 EX-31.1 gemp-20180331ex3112d63af.htm EX-31.1 17969
3 EX-31.2 gemp-20180331ex3126eeb25.htm EX-31.2 18052
4 EX-32.1 gemp-20180331ex321b05f4a.htm EX-32.1 11992
  Complete submission text file 0001558370-18-004320.txt   3917305

Data Files

Seq Description Document Type Size
5 EX-101.INS gemp-20180331.xml EX-101.INS 542948
6 EX-101.SCH gemp-20180331.xsd EX-101.SCH 38451
7 EX-101.CAL gemp-20180331_cal.xml EX-101.CAL 32083
8 EX-101.DEF gemp-20180331_def.xml EX-101.DEF 147626
9 EX-101.LAB gemp-20180331_lab.xml EX-101.LAB 351301
10 EX-101.PRE gemp-20180331_pre.xml EX-101.PRE 277011
Mailing Address 17199 N. LAUREL PARK DRIVE SUITE 401 LIVONIA MI 48152
Business Address 17199 N. LAUREL PARK DRIVE SUITE 401 LIVONIA MI 48152 248-980-6538
Gemphire Therapeutics Inc. (Filer) CIK: 0001638287 (see all company filings)

IRS No.: 472389984 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37809 | Film No.: 18815100
SIC: 2834 Pharmaceutical Preparations